计划明年全球推出口服减肥药Orforglipron 礼来(LLY.US)一度涨4%

Core Viewpoint - Eli Lilly's stock price increased by over 3% following the announcement of successful results from a late-stage clinical trial for its oral weight loss drug Orforglipron, which is set to launch globally next year [1] Group 1: Clinical Trial Results - Orforglipron achieved its primary research goals in a late-stage clinical trial targeting patients with obesity and type 2 diabetes [1] - Patients receiving the highest dose of Orforglipron lost an average of 10.5% of their body weight over a 72-week period, compared to a 2.2% weight loss in the placebo group [1] Group 2: Market Impact - Following the announcement, Eli Lilly's stock price saw a peak increase of 4% before settling at $718.74 [1]